On the basis of these data, we chose lapatinib, a noncovalent pan-ERBB inhibitor approved by FDA as a treatment for breast cancer with HER2 expression (24, 25), as an agent to combine with SHP099 for in vivo testing. The gene discussed is EGFR; the disease is breast cancer.